Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-876-9300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.39 billion
Profitability
Miscellaneous
Employees24,000
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health Inc (NASDAQ:SYNH) announced its earnings results on Tuesday, August, 6th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.02. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. Syneos Health had a net margin of 0.36% and a return on equity of 9.82%. The firm's revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 EPS. View Syneos Health's Earnings History.
When is Syneos Health's next earnings date?
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $3.08-3.26 for the period, compared to the Thomson Reuters consensus estimate of $3.11. The company issued revenue guidance of $4.64-4.75 billion, compared to the consensus revenue estimate of $4.68 billion.
What price target have analysts set for SYNH?
9 Wall Street analysts have issued 12-month price objectives for Syneos Health's shares. Their predictions range from $48.00 to $68.00. On average, they anticipate Syneos Health's share price to reach $57.5714 in the next year. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Price Targets for Syneos Health.
What is the consensus analysts' recommendation for Syneos Health?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.
Has Syneos Health been receiving favorable news coverage?
Headlines about SYNH stock have been trending positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syneos Health earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Syneos Health.
Are investors shorting Syneos Health?
Syneos Health saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 5,930,300 shares, a decrease of 5.3% from the June 30th total of 6,263,000 shares. Based on an average daily volume of 502,300 shares, the short-interest ratio is presently 11.8 days. Currently, 9.7% of the company's stock are sold short. View Syneos Health's Current Options Chain.
Who are some of Syneos Health's key competitors?
Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS) and Luna Innovations (LUNA).
What other stocks do shareholders of Syneos Health own?
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Mr. Alistair Macdonald, CEO & Director (Age 49)
- Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
- Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)
- Mr. Michael Adam Bell, Consultant (Age 63)
- Mr. Robert Parks, Exec. VP & Chief Accounting Officer
Who are Syneos Health's major shareholders?
Syneos Health's stock is owned by many different of retail and institutional investors. Top institutional investors include Thomas H Lee Partners LP (18.55%), BlackRock Inc. (8.25%), Vanguard Group Inc. (7.39%), Mackenzie Financial Corp (2.68%), Viking Global Investors LP (1.74%) and JPMorgan Chase & Co. (1.44%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, Gregory S Rush, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.
Which institutional investors are selling Syneos Health stock?
SYNH stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Price T Rowe Associates Inc. MD, Pictet Asset Management Ltd., Pictet Asset Management Ltd., D. E. Shaw & Co. Inc., Invesco Ltd., Mackenzie Financial Corp and Bank of America Corp DE. View Insider Buying and Selling for Syneos Health.
Which institutional investors are buying Syneos Health stock?
SYNH stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Victory Capital Management Inc., Vanguard Group Inc., Point72 Asset Management L.P., Magnetar Financial LLC, Rothschild & Co. Asset Management US Inc., JPMorgan Chase & Co. and BlackRock Inc.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $51.99.
How big of a company is Syneos Health?
Syneos Health has a market capitalization of $5.38 billion and generates $4.39 billion in revenue each year. The company earns $24.28 million in net income (profit) each year or $2.62 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.View Additional Information About Syneos Health.
What is Syneos Health's official website?
How can I contact Syneos Health?
Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]
MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
